[Absence of bioavailability of HPL following intramuscular application (author's transl)].
Repeated intramuscular application of HPL to pregnant women did not significantly influence serum concentrations of HPL, SP-1 and estriol. Thus, this mode of application seems to be not adequately for substitutional therapy during pregnancy.
D001682:Biological Availability; D004964:Estriol / Q000097:blood; D005260:Female; D006801:Humans; D007273:Injections, Intramuscular; D010928:Placental Lactogen / Q000008:administration & dosage* / Q000097:blood; D011247:Pregnancy; D011268:Pregnancy-Specific beta 1-Glycoproteins / Q000097:blood
D011268:Pregnancy-Specific beta 1-Glycoproteins; D010928:Placental Lactogen; D004964:Estriol
Fehlende Bioverfügbarkeit von HPL nach intramuskulärer Zufuhr.